Comprehensive Analysis of the Chemokine/Cytokine Profiles in Advanced Mycosis Fungoides and Atopic Dermatitis
Authors:
- Manami Takahashi-WatanabeMTManami Takahashi-Watanabe
- Taku FujimuraTFTaku Fujimura
- Emi YamazakiEYEmi Yamazaki
- Ryo AmagaiRARyo Amagai
- Kenta OkaKOKenta Oka
- Yumi KambayashiYKYumi Kambayashi
- Maki OzawaMOMaki Ozawa
- Tomoko ChibaTCTomoko Chiba
- Mayuko Onodera-AmagaiMOMayuko Onodera-Amagai
- Toshiya TakahashiToshiya Takahashi
- Yoshihide AsanoYAYoshihide Asano
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Abstract
Mycosis fungoides (MF) is an indolent form of cutaneous T‐cell lymphoma. Its early lesions are important to be distinguished from atopic dermatitis (AD) because of their similar immune microenvironment. We have previously demonstrated that several chemokines are involved in the pathogenesis of advanced MF. Therefore, we sought to comprehensively analyze the changes in the immune environment during the advanced phase of MF by focusing on serum cytokines and chemokines and to identify potential biomarkers for the early detection of the transition to the advanced phase of MF. Sera from 11 cases of advanced‐stage MF, 16 cases of mild AD (median EASI score = 5.75), 16 cases of severe AD (median EASI score = 28.1), and 21 healthy volunteers were analyzed using the Bio‐Plex 40 multiplex immunoassay system. The results revealed significant increases in immunosuppressive macrophage‐related factors (IL‐4, MIF, CCL3) in MF patients compared to those with AD and healthy controls. In contrast, IL‐2, CCL1, CCL7, CCL21, CCL25, and CCL26 were significantly increased in severe AD patients compared to MF patients and healthy controls. Our findings suggest that several chemokines and cytokines contribute to an immunosuppressive environment favorable for tumor growth, distinguishing MF from AD. Moreover, T‐cell proliferation and migration factors, which are mainly involved in maintaining inflammation, are elevated in severe AD compared to MF. In addition to elucidating the differences in the pathogenesis of these diseases, these factors may be important in the differential diagnosis of early MF and AD. Further studies are warranted to confirm these findings.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP23ym0126041)
- Japan Society for the Promotion of Science (23K19525)
This publication has 24 references indexed in Scilit:
- Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort studyJournal of the American Academy of Dermatology, 2024
- Possible effects of plasminogen activator inhibitor‐1 on promoting angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoidesHematological Oncology, 2024
- Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic TherapiesDermatology and Therapy, 2023
- Single-cell RNA sequencing unveils the communications between malignant T and myeloid cells contributing to tumor growth and immunosuppression in cutaneous T-cell lymphomaCancer Letters, 2022
- Role of chemokines in the crosstalk between tumor and tumor-associated macrophagesClinical and Experimental Medicine, 2022
- Mycosis Fungoides and Its Relationship to Atopy, Serum Total IgE, and Eosinophil CountsClinical Lymphoma Myeloma and Leukemia, 2021
- IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor ProgressionCell, 2020
- Macrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphomaHematological Oncology, 2016
- Proteome and cytokine serum profiling to diagnose a mycosis fungoidesProteomics – Clinical Applications, 2011
- Relative Content of Cytokines in Different Tissues in Mycosis FungoidesBulletin of Experimental Biology and Medicine, 2002